A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-24

Study Completion Date

2022-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

NCT03822832

Dermatitis, Atopic

COMPLETED PHASE2

Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT06585202

Atopic Dermatitis

COMPLETED PHASE2

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT06012812

Moderate to Severe Atopic Dermatitis

ENROLLING_BY_INVITATION PHASE2

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251

Dermatitis, Atopic

ACTIVE_NOT_RECRUITING PHASE2

Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

NCT00757042

Atopic Dermatitis Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatitis, Atopic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spesolimab 600 mg

600 milligrams (mg) solution for subcutaneous (SC) injection of BI 655130 (Spesolimab) were to administered subcutaneously every 4 weeks.

All patients will return 16 weeks post the last treatment for an End of Study (EOS) visit.

Group Type EXPERIMENTAL

Spesolimab

Intervention Type DRUG

Solution for SC injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spesolimab

Solution for SC injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BI 655130

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to the start of any screening procedures
* Patients who completed the 1368-0032 trial and did not prematurely discontinue treatment prior to week 16, and; In the 1368-0032 re-allocation period (V7 to V11):

* If an original non-responder from week 16 (V7), attained at least EASI 50 by last infusion (week 28) or by the EOS.
* If an original responder from week 16 (V7) completed the last visit Week 28 (EOS) or dropped to a EASI 50 score prior to Week 28.
* Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly for the duration of the trial and 16 weeks after last study drug administration. A list of contraception methods meeting these criteria is provided in the patient information.

Exclusion Criteria

* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
* Any new documented active or suspected malignancy except appropriately treated basal cell carcinoma, squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.
* Use of any restricted medication: or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator.
* Active systemic infections during the last two weeks prior to first drug administration.
* Currently enrolled in another investigational device or drug trial, except for 1368-0032.
* Any condition which would prevent the patient continuing on treatment in this trial 1368-0037
* Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse or any condition) other than AD, surgical procedure, psychiatric or social problems, medical examination finding (including vital signs and ECG), or laboratory value at the screening outside the reference range that in the opinion of the investigator is clinically significant and would make the study participant unreliable to adhere to the protocol, comply with all study visits/procedures or to complete the trial, compromise the safety of the patient or compromise the quality of the data.
* History of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No